For $9.99 you can get 57 Poké Gold at its usual rate or 72 Poké Gold as part of the “release celebration” sale. One Poké Gold reduces the pack timer by two hours (so six Poké Gold grants you a ...

Based on technology and cloud defenses provided by Bitdefender, Acronis Cyber Protect Home Office does an excellent job of ...

Macs may need additional antivirus protection in a business environment or high-risk use case. Bitdefender is the best overall Mac antivirus provider when it comes to protection, usability, and ...

Investopedia / NoNo Flores A forward premium results when the forward or expected future price for a currency is greater than the spot price (the price for immediate delivery). It is an indication ...

Australian researchers are about to launch a human trial to treat spinal cord injury by transplanting cells from the noses of paralysed patients into the damaged area. Griffith University ...

Designed for aspiring malware analysts and exploit developers, this course caters to individuals interested in the exploitation of the Win32 APIs to inject shellcode into remote processes.

YouTube is expanding its Premium Lite plan to more countries, offering a lower-cost subscription option with limited advertisements, according to reports. Initially, this paywall plan was launched ...

The drug failed to improve survival for patients with advanced bladder cancer in the trial. There were also a higher number of deaths, opens new tab, associated with complications related to ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Google previously offered a lesser tier of YouTube Premium, called Premium Lite, available at a lower price. YouTube Premium Lite offered an ad-free experience to subscribers until the pilot ...

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment Vandana Singh Fri, Oct 18, 2024, 2:34 PM 2 min read ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead ...